ATMP Symposium for Knowledge Exchange, Innovation, and Future Collaborations

Blog post by Carin Dahlberg, Scientific coordinator NextGenNK

On January 22, 2025, NextGenNK and CCRM Nordic hosted a mini-symposium at Karolinska Institutet, Campus Flemingsberg, with a focus on Advanced Therapy Medicinal Products (ATMP). The event aimed to foster networking within the ATMP field and provide insights into both academic and commercial advancements in Stockholm and Sweden.

NextGenNK and CCRM Nordic co-organized the mini-symposium to strengthen the development of ATMP by combining academic research with industrial expertise. During a half-day event, 14 presentations were delivered by representatives from academia, hospitals, and industry. Together, we aim to create a platform that facilitates innovation, production, and increased adoption of advanced therapies.

The event’s goal was to promote further collaboration and networking among researchers, clinicians, and industry partners, thereby supporting ongoing projects, contributing to the development of new initiatives, and increasing visibility for the ATMP field in Sweden. By bringing together experts and stakeholders, we strived to create a dynamic environment for knowledge sharing and future partnerships.

The mini-symposium was highly successful, with over 150 participants from more than 60 universities and companies. Attendees appreciated the opportunity to network and learn about the latest advancements in ATMP. The positive feedback highlights a strong interest in continued collaboration and development within this exciting field.

ATMP represents a rapidly growing sector in medicine, focusing on developing advanced therapies such as cell and gene therapies to treat previously incurable diseases. Progress in this area points toward more personalized treatments and innovative therapies that have the potential to revolutionize healthcare.

 Read more about the event here

Stockholm Life Tech gets full funding

Stockholm Life Tech is awarded over SEK 16 million from the European Regional Development Fund. The project is run by Region Stockholm and will enable advanced development and production environments in Flemingsberg to be opened to small and medium-sized companies.In Flemingsberg, it is primarily ANA Futura and Vecura that are opened to more small and medium-sized companies working on advanced therapies. Something that can support the growth of small and medium-sized companies in life science.

Stockholm Life Tech gets full funding

Stockholm Life Tech is awarded over SEK 16 million from the European Regional Development Fund. The project is run by Region Stockholm and will enable advanced development and production environments in Flemingsberg to be opened to small and medium-sized companies.

Karin Mellström: “Co-operation is the key to success”

After 10 years as a start-up, CellProtect Nordic Pharmaceuticals has taken a major step forward. Our patient and careful work is now bearing fruit, explains Karin Mellström, CEO and founder. Looking back on her career, she sums it up by saying: “I’d never been bored for a second!”

Go to Top